Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout
Stocks in this Quantisnow insightHealth Care
Quantisnow market dataNASDAQ
EXAI
Exscientia Plc
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2021
Get push alerts for EXAI
Full EXAI profile on Quantisnow Follow EXAI and get a push notification the moment its next story breaks.